CN104274390A - 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 - Google Patents
一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 Download PDFInfo
- Publication number
- CN104274390A CN104274390A CN201410447231.7A CN201410447231A CN104274390A CN 104274390 A CN104274390 A CN 104274390A CN 201410447231 A CN201410447231 A CN 201410447231A CN 104274390 A CN104274390 A CN 104274390A
- Authority
- CN
- China
- Prior art keywords
- timolol
- long
- nanometer
- permeating skin
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 title claims abstract description 207
- 229960004605 timolol Drugs 0.000 title claims abstract description 207
- 238000002360 preparation method Methods 0.000 title claims abstract description 130
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 201000011066 hemangioma Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 107
- 239000000017 hydrogel Substances 0.000 claims abstract description 57
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 239000002674 ointment Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 238000004321 preservation Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000002105 nanoparticle Substances 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 239000002202 Polyethylene glycol Substances 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 11
- -1 carboxy vinyl Chemical group 0.000 claims description 10
- 239000003883 ointment base Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 9
- 235000010234 sodium benzoate Nutrition 0.000 claims description 9
- 239000004299 sodium benzoate Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000005204 segregation Methods 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 6
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 claims description 4
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 claims description 4
- 229940099259 vaseline Drugs 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 229940011037 anethole Drugs 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000010642 eucalyptus oil Substances 0.000 claims description 3
- 229940044949 eucalyptus oil Drugs 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 2
- 239000005792 Geraniol Substances 0.000 claims description 2
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 claims description 2
- 229920000432 Polylactide-block-poly(ethylene glycol)-block-polylactide Polymers 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 2
- 229940113087 geraniol Drugs 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 229920006163 vinyl copolymer Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 13
- 239000000843 powder Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 208000001969 capillary hemangioma Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 206010059866 Drug resistance Diseases 0.000 description 23
- 230000000259 anti-tumor effect Effects 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 229940126586 small molecule drug Drugs 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910021426 porous silicon Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010071054 Eyelid haemangioma Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000036216 Placenta Previa Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410447231.7A CN104274390B (zh) | 2014-09-04 | 2014-09-04 | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410447231.7A CN104274390B (zh) | 2014-09-04 | 2014-09-04 | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104274390A true CN104274390A (zh) | 2015-01-14 |
CN104274390B CN104274390B (zh) | 2017-06-13 |
Family
ID=52250060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410447231.7A Active CN104274390B (zh) | 2014-09-04 | 2014-09-04 | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104274390B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106105A (zh) * | 2015-08-14 | 2015-12-02 | 天津市聚星康华医药科技有限公司 | 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法 |
CN106362223A (zh) * | 2016-08-26 | 2017-02-01 | 南通纺织丝绸产业技术研究院 | 多孔丝素蛋白微针给药装置及其制备方法 |
CN107405313A (zh) * | 2015-04-06 | 2017-11-28 | 株式会社Lg生活健康 | 难溶性药物传递用的可溶性微针 |
CN107469065A (zh) * | 2017-07-19 | 2017-12-15 | 广州医科大学 | 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用 |
CN109528693A (zh) * | 2018-12-20 | 2019-03-29 | 武汉科福新药有限责任公司 | 一种雷帕霉素巴布剂及其制备方法 |
CN111773226A (zh) * | 2019-06-26 | 2020-10-16 | 首都医科大学附属北京儿童医院 | 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途 |
CN112933096A (zh) * | 2019-12-11 | 2021-06-11 | 中国科学院上海药物研究所 | 丁酰噻吗洛尔在制备治疗浅表型、混合型或深部血管瘤的药物中的用途 |
CN115252718A (zh) * | 2021-04-30 | 2022-11-01 | 武汉科福新药有限责任公司 | 一种含噻吗洛尔的透皮贴剂及其制备方法 |
GB2621775A (en) * | 2019-09-04 | 2024-02-21 | Wuhan Conform Pharmaceutical Co Ltd | Transdermal permeation enhancing composition and application thereof in timolol preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102006864A (zh) * | 2007-10-19 | 2011-04-06 | 维克多塞加伦波尔多第二大学 | β-阻断剂在制备用于治疗血管瘤药物中的用途 |
CN103330680A (zh) * | 2013-05-31 | 2013-10-02 | 袁伟恩 | 纳米药物透皮制剂及其制备方法 |
-
2014
- 2014-09-04 CN CN201410447231.7A patent/CN104274390B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102006864A (zh) * | 2007-10-19 | 2011-04-06 | 维克多塞加伦波尔多第二大学 | β-阻断剂在制备用于治疗血管瘤药物中的用途 |
CN103330680A (zh) * | 2013-05-31 | 2013-10-02 | 袁伟恩 | 纳米药物透皮制剂及其制备方法 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107405313B (zh) * | 2015-04-06 | 2021-04-13 | 株式会社Lg生活健康 | 难溶性药物传递用的可溶性微针 |
CN107405313A (zh) * | 2015-04-06 | 2017-11-28 | 株式会社Lg生活健康 | 难溶性药物传递用的可溶性微针 |
CN105106105A (zh) * | 2015-08-14 | 2015-12-02 | 天津市聚星康华医药科技有限公司 | 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法 |
CN106362223A (zh) * | 2016-08-26 | 2017-02-01 | 南通纺织丝绸产业技术研究院 | 多孔丝素蛋白微针给药装置及其制备方法 |
CN106362223B (zh) * | 2016-08-26 | 2019-05-03 | 南通纺织丝绸产业技术研究院 | 多孔丝素蛋白微针给药装置及其制备方法 |
CN107469065A (zh) * | 2017-07-19 | 2017-12-15 | 广州医科大学 | 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用 |
CN107469065B (zh) * | 2017-07-19 | 2021-05-18 | 广州医科大学 | 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用 |
CN109528693A (zh) * | 2018-12-20 | 2019-03-29 | 武汉科福新药有限责任公司 | 一种雷帕霉素巴布剂及其制备方法 |
CN109528693B (zh) * | 2018-12-20 | 2022-03-01 | 武汉科福新药有限责任公司 | 一种雷帕霉素巴布剂及其制备方法 |
CN111773226A (zh) * | 2019-06-26 | 2020-10-16 | 首都医科大学附属北京儿童医院 | 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途 |
GB2621775A (en) * | 2019-09-04 | 2024-02-21 | Wuhan Conform Pharmaceutical Co Ltd | Transdermal permeation enhancing composition and application thereof in timolol preparation |
GB2600633B (en) * | 2019-09-04 | 2024-04-03 | Wuhan Conform Pharmaceutical Co Ltd | Transdermal permeation enhancing composition and application thereof in timolol preparation |
GB2621775B (en) * | 2019-09-04 | 2024-05-15 | Wuhan Conform Pharmaceutical Co Ltd | Transdermal permeation enhancing composition and application thereof in timolol preparation |
CN112933096A (zh) * | 2019-12-11 | 2021-06-11 | 中国科学院上海药物研究所 | 丁酰噻吗洛尔在制备治疗浅表型、混合型或深部血管瘤的药物中的用途 |
CN112933096B (zh) * | 2019-12-11 | 2023-06-13 | 中国科学院上海药物研究所 | 丁酰噻吗洛尔在制备治疗浅表型、混合型或深部血管瘤的药物中的用途 |
CN115252718A (zh) * | 2021-04-30 | 2022-11-01 | 武汉科福新药有限责任公司 | 一种含噻吗洛尔的透皮贴剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104274390B (zh) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104274390A (zh) | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 | |
CN106139144B (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金-碳纳米球及其制备方法与应用 | |
WO2021056815A1 (zh) | 一种化疗免疫组合药物及其制备方法 | |
CN103705469B (zh) | 一种和厚朴酚纳米粒及其制备方法 | |
CN110522910A (zh) | 基于金属有机框架纳米给药系统及其制备方法和应用 | |
CN103330680A (zh) | 纳米药物透皮制剂及其制备方法 | |
Xue et al. | Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma | |
US10206972B2 (en) | Anti-vascular disease and antitumor pharmaceutical composition and use thereof | |
WO2010118683A1 (zh) | 含索拉非尼的海藻酸钠靶向缓释微球血管拴塞剂及其制备和应用 | |
Li et al. | Mussel-inspired “plug-and-play” hydrogel glue for postoperative tumor recurrence and wound infection inhibition | |
CN102302449A (zh) | 一种水包油型肉桂醛纳米乳药物 | |
CN104288093B (zh) | 纳米药物透皮制剂在肿瘤中的应用 | |
CN104352442B (zh) | 一种米非司酮壳聚糖缓释微球制剂及其制备方法 | |
CN104721131B (zh) | 一种用于肿瘤原位治疗的凝胶制剂及制备方法 | |
Liu et al. | Thermosensitive selenium hydrogel boosts antitumor immune response for hepatocellular carcinoma chemoradiotherapy | |
CN113975249B (zh) | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 | |
KR20240041285A (ko) | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 | |
Tian et al. | Engineering of an endogenous hydrogen sulfide responsive smart agent for photoacoustic imaging-guided combination of photothermal therapy and chemotherapy for colon cancer | |
CN105456200A (zh) | 一种提高难溶性药物口服生物利用度的纳米粒微球的制备方法及应用 | |
CN101721375B (zh) | 胰岛素缓释微米球组合物及其制备方法 | |
CN102274179A (zh) | 一种乙酰甲喹纳米乳抗菌药物及其制备方法 | |
CN108113976B (zh) | Th-302制剂、制备方法及其用途 | |
JP2001055323A (ja) | 粉末状経鼻投与用組成物 | |
CN101810640B (zh) | 含有冰片和白矾的复合纳米乳及其制备方法 | |
CN1772127A (zh) | 七味解毒活血膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181017 Address after: 200011 Shanghai Huangpu District manufacturing Bureau Road 639 Patentee after: The Affiliated No. 9 People's Hospital of Shanghai Jiaotong University School of Medicine Address before: 200011 Shanghai Huangpu District manufacturing Bureau Road 639 Co-patentee before: Yuan Weien Patentee before: Zheng Jiawei |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201130 Address after: Room 03, 3 / F, building 10, 11, 15, 68 Beiqing Road, Haidian District, Beijing 100089 Patentee after: BEIJING MERSON PHARMACEUTICAL Co.,Ltd. Address before: 200011 No. 639, manufacturing Bureau Road, Shanghai, Huangpu District Patentee before: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |